$APTO, $CDMO, $ENDP, $IGMS, $ILMN

Here are some of the many biotech and pharma stocks that have been given big Northside targets for Y 2020 by Key sector analysts, as follows:

Aptose Biosciences Inc. (NASDAQ:APTO) was started with a new Buy rating and a 10 price target at Piper Jaffray on 9 January. This represented well over 80% in implied upside from the prior 5.32 closing price, but shares initially rose 8% to 7.75 after the call. The 52-wk trading range is 1.576 – 6.04, and the shares had been above the Aptose closed on a $74-M capital raise at 4.00/share via a stock sale in December.

Avid Bioservices Inc. (NASDAQ:CDMO) was reiterated as Buy with a 10 price target at Janney on 6 January. The latest price was 6.95, implying 44% upside if its analysis is correct. Janney is seeing an increased strategic value in Y 2020 as a pure-play monoclonal producer that is still a small-cap stock competing with larger companies at a time when the global capacity for biologics manufacturing remains constrained. The firm also sees an inflection point to faster growth and profitability coming in Y 2020.

Endo International PLC (NASDAQ:ENDP) was upgraded to Overweight from Neutral and its target price was raised to 7 from 5 at Piper Jaffray on 3 January. Endo recently traded at 4.60, implying more than 52% upside if the firm is correct. It is a $1-B market cap company that recently launched a generic version of Afinitor tablets in the United States via its Par Pharma unit. The company’s news release from December indicated that the name brand drug saw approximately $412-M in sales over the past Quarters.

IGM Biosciences Inc. (NASDAQ:IGMS), a $1-B market cap company that is into research and development of engineered therapeutic engineered Immunoglobulin M (IgM) antibodies, was reiterated as Overweight at Piper Jaffray on 6 January. What stood out here was that the 26 target price was raised to 53. That represents about 60% upside from the recent 32.42 share price. The 52-wk trading range is 16.10 – 57.42.

Illumina Inc. (NASDAQ:ILMN), which is the leader in gene sequencing and genomics, was started as Buy with a 385 target price in a new sector call at Citigroup. Shares recently traded at 322.15, for an implied upside of 17% if the Citigroup call is correct. This was 1 of the more Bullish targets in that sector call, and some of the peer companies were viewed as Hold/Neutral positions rather than with big Buy ratings and big implied upside. On 9 January, Piper Jaffray reiterated its Overweight rating and raised its target price to 370 from 340.

Have a terrific week

  APTO, biopharmas, Bullish, buy, CDMO, development, ENDP, growth, IGMS, ILMN, northside, pharma, potential, price, profitability, research, target

The following two tabs change content below.

• Bio
• Latest Posts

HEFFX Australia

HEFFX has become one of Asia’s leading financial services companies with interests in Publishing, Private Equity, Capital Markets, Mining, Retail, Transport and Agriculture that span every continent of the world. Our clearing partners have unprecedented experience in Equities, Options, Forex and Commodities brokering, banking, physical metals dealing, floor brokering and trading.

Latest posts by HEFFX Australia (see all)

• Tesla (NASDAQ:TSLA) Stock Update - December 2, 2020
• Amazon (NASDAQ:AMZN) Stock Update and Technical Analysis from Metastock - December 2, 2020
• Facebook (NASDAQ:FB) Charts Show More Upside - December 2, 2020